Yves Huwyler
Plus aucun poste en cours
Profil
Yves Huwyler formerly worked at Osiris Therapeutics, Inc., as Independent Non-Executive Director, Prolexys Pharmaceuticals, Inc., as Director, ReVerb Networks, Inc., as Director, and Huwyler Private Equity GmbH, as Owner.
Mr. Huwyler received his graduate degree from the University of Zurich.
Anciens postes connus de Yves Huwyler
| Sociétés | Poste | Fin |
|---|---|---|
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur/Membre du Conseil | 31/03/2017 |
| Huwyler Private Equity GmbH | Corporate Officer/Principal | 31/03/2017 |
ReVerb Networks, Inc.
 ReVerb Networks, Inc. BroadcastingConsumer Services ReVerb Networks, Inc. develops and designs an integrated radio and antenna systems. The company was founded in 2007 and is headquartered in Sterling, VA. | Directeur/Membre du Conseil | 31/03/2017 |
| OSIRIS THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Formation de Yves Huwyler
| University of Zurich | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
ReVerb Networks, Inc.
ReVerb Networks, Inc. BroadcastingConsumer Services ReVerb Networks, Inc. develops and designs an integrated radio and antenna systems. The company was founded in 2007 and is headquartered in Sterling, VA. | Consumer Services |
| Huwyler Private Equity GmbH |